Summary of US guidelines on systemic therapy for melanoma

August 19, 2016

Summary

The NCCN ((National Comprehensive Cancer Network) Guidelines for Melanoma represent an effort to distill and simplify an enormous body of knowledge and experience into fairly simple management algorithms.

These guidelines are intended as a point of departure, recognizing that all clinical decisions about individual patient management must be tempered by the clinician’s judgment and other factors, such as local resources and expertise as well as the individual patient’s needs, wishes, and expectations.

Systemic therapies for treatment of metastatic disease are all associated with considerable risk of toxicity, and treatment decisions should be informed by consideration of these risks and assessment of factors that may increase risk of toxicity.

Please see the full NCCN Guidelines for Melanoma (available at www.NCCN.org) for a summary of safety data and recommendations for risk assessment, monitoring, detection, prevention, and management of toxicities in patients receiving systemic therapy for metastatic melanoma.

Source:

Colt, DG, et al.  NCCN (National Comprehensive Cancer Network) Guidelines Insights: Melanoma, Version 3.2016J Natl Compr Canc Netw 2016;14(8):945–958
http://www.jnccn.org/content/14/8/945.abstract (Open Access article available)